Lopinavir/r [lopinavir/ritonavir] plus saquinavir salvage therapy in HIV-infected children with NRTI [nucleoside reverse transcriptase inhibitors] and/or NNRTI [non nucleoside reverse transcriptase inhibitors] failure: PK [pharmacokinetics] and two-year treatment follow up

Trial Profile

Lopinavir/r [lopinavir/ritonavir] plus saquinavir salvage therapy in HIV-infected children with NRTI [nucleoside reverse transcriptase inhibitors] and/or NNRTI [non nucleoside reverse transcriptase inhibitors] failure: PK [pharmacokinetics] and two-year treatment follow up

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Lopinavir/ritonavir; Saquinavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Apr 2015 NCT reports actual enrollment as 50, info retained as per results published.
    • 04 Jun 2010 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top